Overview

A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status:
RECRUITING
Trial end date:
2026-10-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally
Phase:
PHASE2
Details
Lead Sponsor:
S-INFINITY Pharmaceuticals Co., Ltd